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Type 1 diabetes mellitus (t1dm) is a long-term degenerative disease that begins when the body’s defense mechanism starts to destroy 
its own pancreatic β-cells.1,2 While the exact aetiology of 
the disease is unknown, several triggers are thought to 
play a role in disease causation, including genetic, epi- 
genetic and environmental factors. Previously, T1DM 
was thought to affect only children and thus termed 
juvenile or childhood diabetes mellitus; however, as 
a result of technological advancements in diagnostic 
tools, it is now understood that it occurs at any age.1,2 
While T1DM affects both genders equally, there are 
racial disparities in terms of prevalence, with the disease 
being more common among Caucasian Americans 
compared to African Americans.3,4
Generally, T1DM is considered the most taxing 
form of diabetes mellitus (DM) and is characterised by 
severe insulin deficiency and hyperglycaemia.5 Early 
symptoms include increased thirst, appetite and weakness, 
frequent urination and weight loss.6 Uncontrolled hyper- 
glycaemia may subsequently result in multiorgan damage 
involving the eyes, kidneys, nerves and heart, among other 
organs.7 Unfortunately, there is no cure for the disease 
yet; as such, affected patients need to self-medicate and 
take daily doses of insulin for survival.8 Although type 
2 DM (T2DM) accounts for the majority of the overall 
economic burden of DM due to its higher prevalence, 
the economic burden is greater on individual patients 
with T1DM.9
Overall, the prevalence of T1DM is rising steadily, 
with an annual global increase of over 3%, which is 
projected to double in the next 20 years.10 For many 
European and North American countries, the rising 
incidence of T1DM began around the mid-20th century, 
coinciding with increased industrialisation.11,12 Among 
other lifestyle modifications, breastfeeding patterns 
review
العالقة بني اجلزيئات النشطة بيولوجًيا يف حليب الثدي وداء السكري من النوع األول
تاج الدين يحيا و يوفوما �صمي�صري
abstract: The association between breastfeeding and type 1 diabetes mellitus (T1DM) is controversial. However, 
several recent studies have established a link between these two factors, necessitating a need to review this subject 
to raise public awareness. Current research indicates that breast milk contains a variety of bioactive substances 
including immunoglobulins, oligosaccharides, insulin, lactoferrin, lysozyme, cytokines, epidermal growth factors, 
leukocytes, nucleotides, beneficial bacteria and vitamins. Such substances strengthen the breastfeeding infant’s 
immune system, both directly, by increasing gut microbiota diversity and attacking harmful bacteria and pro-
inflammatory molecules, and indirectly, by increasing thymus performance. Accordingly, a lack of or inadequate 
breastfeeding may predispose infants to several autoimmune disorders, including T1DM. Nursing mothers and 
caregivers are therefore advised to follow optimal breastfeeding practices prior to introducing complementary foods.
Keywords: Breastfeeding; Type 1 Diabetes Mellitus; Autoimmune Diseases; Immunoglobulins; Oligosaccharides; 
Review Literature.
امللخ�ص: العالقة بني الر�صاعة الطبيعية وداء ال�صكري من النوع الأول مثرية للجدل. ومع ذلك فقد اأثبتت العديد من الدرا�صات احلديثة 
احلالية  الأبحاث  ت�صري  العام.  الوعي  م�صتوى  لرفع  املو�صوع  هذا  مراجعة  اإىل  احلاجة  ي�صتدعي  مما  العاملني  هذين  بني  �صلة  وجود 
قليلة  ال�صكريات  املناعية،  الغلوبولينات  ذلك  يف  مبا  بيولوجًيا  الن�صطة  املواد  من  متنوعة  جمموعة  على  يحتوي  الثدي  حليب  اأن  اإىل 
التعدد، الأن�صولني، الالكتوفريين، الليزوزمي، ال�صيتوكينات، عوامل منو الب�رشة، كريات الدم البي�صاء، النيوكليوتيدات، البكترييا النافعة 
والفيتامينات. مثل هذه املواد تقوي اجلهاز املناعي لدى الر�صع املعتمدين على الر�صاعة الطبيعية �صواء ب�صكل مبا�رش وذلك من خالل 
زيادة تنوع الأحياء املجهرية املعوية ومهاجمة البكترييا ال�صارة واجلزيئات امل�صببة لاللتهاب او ب�صكل غري مبا�رش عن طريق زيادة 
اأداء الغدة الزعرتية. وفًقا لذلك قد يوؤدي نق�س الر�صاعة الطبيعية اأوعدم كفايتها اإىل تعري�س الر�صع اإىل العديد من ا�صطرابات املناعة 
الذاتية، مبا يف ذلك داء ال�صكري من النوع الأول. لذلك ُتن�صح الأمهات املر�صعات ومقدمي الرعاية باتباع املمار�صات امُلثلى للر�صاعة 
الطبيعية قبل اإدخال الأطعمة التكميلية.
الكلمات املفتاحية: ر�صاعة طبيعية؛ داء ال�صكري من النوع الأول؛ اأمرا�س املناعة الذاتية؛ غلوبولينات مناعية؛ �صكريات قليلة التعدد؛ مراجعة 
الأدبيات.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
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changed due to the introduction of infant feeding 
alternatives such as formula. The loss of immunological 
function due to inadequate or inappropriate breast- 
feeding habits may contribute to the rising incidence 
of T1DM. This review therefore aimed to examine the 
association between T1DM and the immunological 
function of bioactive molecules in breast milk.
Association of Bioactive 
Molecules with Breastfeeding
The role of breast milk in the aetiology and prevention 
of T1DM is controversial, with certain studies showing 
a protective effect and others reporting predisposing 
or no effects at all.13–15 In a meta-analysis of 25 studies 
with 226,508 participants from 12 countries, Yan et al. 
found that breastfeeding resulted in a reduced risk of 
DM triggers.13 Importantly, 17 of these studies indicated 
a dose-response relationship between breastfeeding 
duration and a lowered risk of childhood obesity. In 
another meta-analysis involving 155,392 Norwegian 
and Danish children, Lund-Blix et al. reported that 
T1DM was related to the early introduction of infant 
formula, with non-breastfed children having a two-fold 
increased risk of disease compared to those who were 
breastfed.14 Nevertheless, in a meta-analysis involving 
43 observational studies of 9,874 individuals with 
T1DM, Cardwell et al. observed a weak link between 
exclusive breastfeeding and T1DM.15 Many factors, 
particularly the experimental designs of these studies 
and variations in breastfeeding patterns in different 
countries, could be responsible for these inconsistent 
results. However, studies that report weak or negative 
effects usually monitor breastfeeding to an imprecise 
degree, without considering whether breastfeeding is 
exclusive or complementary.
Exclusive breastfeeding without vitamin supple- 
mentation may cause vitamin D deficiency in infants, 
particularly if the mother herself is deficient.16 It may 
also result in vitamin E deficiency as vitamin E content 
in breast milk decreases as colostrum matures.17 Vitamin 
E scavenges free radicals, blocking infiltrating toxins 
and cytokines and protecting cells, including the pan- 
creatic islet cells. Deficiencies of both vitamins may 
play a role in the pathogenesis of T1DM.18,19 Giulietti 
et al. reported the overexpression of pro-inflammatory 
cytokines, reduced thymus performance and pancreatic 
islet dysfunction in non-obese diabetic mice kept 
away from ultraviolet light and fed with a vitamin 
D-depleted diet.20 In a Finnish birth cohort study, 
Hyppönen et al. found that daily supplementation 
of 200 IU of vitamin D was associated with a lower 
incidence of T1DM among children.21 In a prospective 
clinical study of both T1DM and T2DM patients, 
vitamin E supplementation decreased blood glucose 
levels and reduced the progression of the disease.22
According to Virtanen et al., complementary 
feeding may yield no effect if this feeding consists of 
dietary formulas containing certain complex proteins.23 
Similarly, Chia et al. showed that dietary A1 β-casein 
may affect glucose homeostasis and induce progression 
to T1DM in non-obese diabetic mice.24 Gluten in 
cereals is also linked with increased T-cell reactivity, 
with diabetogenic effects in rodents.25 Additionally, 
breastfeeding from containers, which are often coated 
with preservatives and anti-rust agents such as 
bisphenol A (BPA), may affect breastfeeding outcomes.26
In a study of new and used baby bottles in Iran, BPA 
levels ranged from 0.49–8.58 μg/L and 0.63–2.47 μg/L, 
respectively.26 In pregnant rats, BPA doses as low as 
0.5 μg/L were found to induce persistent islet insulin 
hypersecretion for up to one year.27 
The duration of breastfeeding and the age at which 
complementary foods are administered may also deter- 
mine the protective role or otherwise of breast milk 
on TIDM pathogenesis. Short-term breastfeeding 
(<3 months) and the early or late introduction of 
complementary foods (<4 months and ≥6 months, 
respectively) are risk factors for T1DM.28 Additionally, 
the introduction of cereals before three months of 
age may be related to early β-cell autoimmunity.29 
Furthermore, certain maternal factors and prenatal 
lifestyle choices such as tobacco smoking, age, mode 
of birth and psychological stress levels may predispose 
an infant to T1DM.30–32 These factors may also be 
linked to breastfeeding outcomes.
Mechanistic Links 
Breast milk has been found to contain various anti- 
pathogenic and anti-inflammatory bioactive molecules, 
some of which can confer infants with lifelong immunity 
against many diseases, including T1DM.33 Thus, breast 
milk can be described as a medium through which the 
maternal defense mechanism trains the immune system 
of the infant.34 Established mechanisms through which 
breast milk prevents T1DM and other autoimmune 
diseases are outlined in Table 1.33,35–55
reduced gut permeability and 
priming of the immune system
The diversity of the gut microbiota—the composition of 
which is influenced by various environmental factors 
such as diet and lifestyle—is important in the aetiology 
and prevention of T1DM. Homeostatically imbalanced 
microbiota, as characterised by a high preponderance 
of certain bacteria, increases intestinal permeability, 
eliciting autoantibodies and causing β-cell auto- 
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immunity, the hallmark of T1DM.35 Individuals with 
T1DM have less stable and diverse microbiota comp- 
ared to non-diabetics.36,56 The most frequently reported 
microbiome imbalance in diabetic individuals is a 
decreased Firmicutes population with a corresponding 
increase in the Bacteroides genus, the opposite of 
which is usual in non-diabetics.36
In experimental mice, microbiota imbalance was 
found to decrease tolerance to food antigens and the 
proportions of regulatory T-cells (Tregs) in the intestinal 
lamina propria, causing intestinal inflammation.37 This 
results in high intestinal permeability, inducing insulitis 
or allowing more exogenous antigens into the mucosal 
immune system. Studies of obese and non-obese diabetic 
mice have observed that this leads to increased cytokine 
production that may attack and damage pancreatic 
β-cells.57–59 Bacterial metabolites may also attack the 
pancreatic islet directly. This was shown during a study 
of mice in which Streptomyces-derived toxins impaired 
glucose tolerance, reducing islet size and β-cell mass 
at low doses via adenosine triphosphatase inhibition.60 
The innate immune system—the body’s first defence 
mechanism after birth—is weak and lacks important 
components. In healthy infants, a developing gut 
microbiome undergoes several stages of maturation in 
which the ingestion of breast milk is considered the 
most important factor.61 This is possible because breast 
milk contains many beneficial bacteria and bioactive 
molecules. Diverse groups of beneficial bacteria in 
breast milk reduce gut permeability, promote gut 
microbiota diversity and maturation as well as boost 
immunological and metabolic function.38 
Breast milk contains high levels of Lactobacillus 
and Bifidobacterium species, which promote the growth 
of Firmicutes bacteria.61,62 Firmicutes deficiency has been 
reported in individuals with T1DM.36,56 Bacteroides 
species are also present in breast milk and increase gut 
diversity and maturation.61 Gut bacteria achieve these 
functions in vitro by either naturally killing pathogenic 
bacteria during the competition for food and survival 
or by producing antimicrobial effects.63,64
Insulin is another bioactive molecule found in 
breast milk; this hormone enhances gut maturation 
and reduces gut permeability to macromolecules.39 In 
addition, insulin in breast milk may induce tolerance 
to blood insulin and prevent T1DM pathogenesis.39 
Breast milk insulin enhances the diversity of the gut 
microbiota by boosting the growth of some members 
of the Gammaproteobacteria family and reducing the 
Streptococcaceae population.40 Gammaproteobacteria 
are involved in the maturation of infant gut microbiota, 
primarily in the first week after birth.41 Insulin and 
leptin, another hormone in breast milk, also influence gut 
microbiota diversity by suppressing certain microbial 
metabolic pathways associated with intestinal inflamm- 
ation while promoting beneficial ones.40
Oligosaccharides are non-digestible sugars in 
breast milk that promote the growth of protective 
bacteria in the colon.33 The non-digestible properties 
of oligosaccharides allow these molecules to escape the 
acidic medium of the small intestine into the colon 
Table 1: Bioactive molecules in breast milk and their role 
in type 1 diabetes mellitus risk reduction33,35–55
Category Molecule Potential roles
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Ig = immunoglobulin; CD = cluster of differentiation; miRNAs = microri- 
bonucleic acids; EGFs = epidermal growth factors; IGF = insulin-like growth 
factor; IL = interleukin.
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where they produce short-chain fatty acids.42 These 
fatty acids enhance the growth of probiotic species, 
including Lactobacillus and Bifidobacterium, resulting 
in a balanced microbiome.43 In an in vitro study, oligo- 
saccharides were found to inhibit and block harmful 
intestinal microorganisms from binding to their normal 
targets in the epithelial cells, thus reducing their 
population.44 Oligosaccharides were also reported to 
confer a protective effect in a murine model of T1DM.65
The administration of oligosaccharides was shown 
to influence microbiota diversity and produce short-
chain fatty acids in non-obese diabetic mice, reversing 
DM progression.66,67
Breast milk also contains large quantities of 
secretory immunoglobulin (Ig) A, which accounts 
for the majority of the Igs in human breast milk.33,43 
Besides IgA, there are four other types of Igs in breast 
milk: IgE, IgG, IgM and IgD.45 Breast milk secretory 
IgA helps train the immune system of newborns 
against enteric pathogens acquired through maternal 
exposure.33,43 Breast milk also contains certain bio- 
active substances capable of stimulating IgA secretion 
in infants.43 Secretory IgA can neutralise infectious 
agents and reduce the inflammatory effects of other 
antibodies.68 Some children with DM are both IgA- 
and IgG-deficient.69
Lactoferrin, an iron-binding glycoprotein, possesses 
several anti-infective properties that form part of the 
innate defense mechanism conferred by mature human 
breast milk.46 Lactoferrin has a high binding affinity for 
iron, thus limiting its availability to bacteria and other 
microorganisms.43 In the intestine, lactoferrin may bind 
to certain receptors, such as toll-like receptors (TLRs) 
and the cluster of differentiation (CD)14 gene, thereby 
blocking the attachment of pathogens to the intestinal 
epithelium.47 In the stomach, lactoferrin combines with 
pepsin to form lactoferrincin, an antimicrobial agent 
powerful enough to damage the cell membrane of 
Gram-negative bacteria.70,71 Lactoferrin also strengthens 
neonate immunity by inhibiting tumour necrosis 
factor-α and interleukin (IL)-1β, as well as initiating the 
maturation of lymphocytes and assisting antioxidation 
processes.72 Adequate levels of lactoferrin have been 
reported to improve diabetic conditions, while their 
decline in obese individuals has been linked to insulin 
resistance.73,74 
Other molecules present in breast milk include 
lysozyme, caseins, cytokines, epidermal growth factors 
(EGFs), leukocytes and nucleotides. Lysozyme is an 
antibacterial enzyme that works together with lacto- 
ferrin in the stomach to destroy Gram-negative bacteria.75 
Lysozyme can also degrade bacteria independently by 
breaking β-glycoside chains in the bacterial cell wall.48 
Caseins are a family of highly glycosylated proteins; 
they account for up to 40% of the proteins present in 
breast milk (mainly β-casein) and functionally boost 
newborn immunity.43 A minor subunit known as 
κ-casein mimics a receptor analogue, preventing the 
attachment of bacteria to the mucosal epithelium.76 
Cytokines are signalling molecules that mediate, 
regulate and modulate immune responses, with one 
example being the anti-inflammatory cytokine IL-10.44,49
While many growth factors are present in breast milk, 
EGFs are of particular importance, as these factors aid 
in the healing and maturation of the intestinal mucosa, 
nervous system and endocrine system, among others.50 
Breast milk, particularly colostrum, contains high 
concentrations of leukocytes, of which approximately 
10% are lymphocytes, T-cells, macrophages, neutrophils 
and antibody-producing B-cells.51 These cells survive 
passage into the newborn intestines, where they 
phagocytise microbial pathogens and strengthen the 
infant’s immune response. Triglycerides are also an 
important component of breast milk. The newborn 
stomach digests triglycerides using lingual and gastric 
lipases, releasing free fatty acids and monoglycerides. 
These two products strengthen the immune system 
and—through their lytic activities—protect the 
newborn from various viruses, bacteria and some 
protozoa, specifically those of the Giardia family.52 
Nucleotides are also present in human breast milk 
and enhance immune function in infants.53 Finally, 
apart from vitamin D, breast milk contains sufficient 
quantities of all vitamins essential for normal growth 
in children.54 
enhanced thymus size and function
During both the fetal and neonatal periods, the 
primary function of the thymus is to assist in the 
development and maturation of T-lymphocytes or 
T-cells.77 This specific type of white blood cell protects 
the body from microbial infections and other risks 
by either controlling immune reactions or directly 
attacking infected or cancerous cells.77,78 After puberty, 
the thymus reduces its function and slowly decreases 
in size until it is replaced by fat at about 75 years of 
age.77,79 Nevertheless, during its active phase, the 
thymus produces enough T-cells to protect the body 
from autoimmunity for life.77
Due to its role in maintaining a strong neonate 
defence mechanism, loss of thymus function may be 
implicated in the pathogenesis of several diseases. 
For instance, autoimmune-mediated DM begins with 
the failure of the thymus to develop a normal β-cell 
self-tolerance.80 Dysfunctional thymic activity along 
with expression of insulin-like growth factor 2 is also 
suspected in certain cases of insulin resistance.80 One 
animal study noted the development of autoimmune 
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diseases in mice whose thymuses were removed.81 
While scientists are still skeptical about the role of 
thymus size in its performance, the fact that the organ 
is largest during childhood when an individual is most 
prone to immunological threats seems to indicate 
that increased thymus size is associated with better 
immunity.77
Several factors may influence thymus size and 
activity, potentially leading to the prevention of 
autoimmune diseases such as T1DM. Some studies 
show that breast milk may enlarge the thymus gland, 
either directly via certain components in breast milk 
or indirectly as a result of the effects of breast milk 
on infant gut microbiota.82,83 Breast milk contains 
CD4+ T-cells, which are passed into the thymus of 
the infant where they help train CD8+ T-cells to 
fight pathogens.55 Breast milk also contains maternal 
cytotoxic T-lymphocytes which pass into the thymus 
of infants, after which they find their way to the 
lymphatic tissues in the ileum where they prevent the 
growth of harmful bacteria.84
Microribonucleic acids (miRNAs) that regulate 
post-transcription immune cell activity are also 
present in breast milk.85 Notably, miRNA-155 plays 
a key role in regulating thymus Treg and T-helper-2 
cell development in humans and animals.86,87 In mice, 
miRNA-449a regulates thymus medullary epithelial 
cell development.88 Certain hormones involved in 
thymus development are also present in breast milk. 
Among these are corticosteroids, which control 
thymus epithelial differentiation and the production of 
thymus corpuscles.89,90 In addition, IL-7 is also present 
in breast milk and regulates thymus size. Collinson 
et al. reported that the children of malnourished 
mothers have small thymuses, with small thymus size 
linked with low IL-7 levels in maternal breast milk.91
Conclusion
Breast milk contains a wide variety of bioactive sub- 
stances which functionally protect the infant’s immune 
system from autoimmune disorders by increasing the 
population of beneficial bacteria in the gut, attacking 
pathogenic bacteria and pro-inflammatory molecules as 
well as increasing thymus size and performance. As such, 
inadequate breastfeeding may predispose an infant 
to autoimmune diseases, including T1DM. Nursing 
mothers and caregivers are therefore advised to follow 
optimal breastfeeding practices. For babies unable to 
be breastfed, perhaps due to maternal death or the 
risk of vertical disease transmission, the bioactive sub- 
stances mentioned in breast milk can be used to form- 
ulate infant feeding formula for such babies.
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